Therapeutic advantage of pro-electrophilic drugs to activate the Nrf2/ARE pathway in Alzheimer's disease models
about
Are Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and Neurodegeneration?Krebs Cycle Intermediates Protective against Oxidative Stress by Modulating the Level of Reactive Oxygen Species in Neuronal HT22 Cells.Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate.Protective effects of carnosic acid against mitochondria-mediated injury in H9c2 cardiomyocytes induced by hypoxia/reoxygenation.An Intracellular Amyloid-β/AβPP Epitope Correlates with Neurodegeneration in those Neuronal Populations Early Involved in Alzheimer's Disease.Protective Effects of 6-(Methylsulfinyl)hexyl Isothiocyanate on Aβ-Induced Cognitive Deficit, Oxidative Stress, Inflammation, and Apoptosis in Mice
P2860
Therapeutic advantage of pro-electrophilic drugs to activate the Nrf2/ARE pathway in Alzheimer's disease models
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Therapeutic advantage of pro-e ...... in Alzheimer's disease models
@ast
Therapeutic advantage of pro-e ...... in Alzheimer's disease models
@en
type
label
Therapeutic advantage of pro-e ...... in Alzheimer's disease models
@ast
Therapeutic advantage of pro-e ...... in Alzheimer's disease models
@en
prefLabel
Therapeutic advantage of pro-e ...... in Alzheimer's disease models
@ast
Therapeutic advantage of pro-e ...... in Alzheimer's disease models
@en
P2093
P2860
P356
P1476
Therapeutic advantage of pro-e ...... in Alzheimer's disease models
@en
P2093
Anthony Nutter
James Parker
Kevin M Lopez
Kunio Kosaka
Nobuki Nakanishi
Scott R McKercher
Stuart A Lipton
Takumi Satoh
Tayebeh Rezaie
P2860
P356
10.1038/CDDIS.2016.389
P407
P577
2016-12-01T00:00:00Z